Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial In Progress
660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)